SEC Form 4 · accession 0001209191-17-061662
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mitchell S Levine
Officer — Chief Financial Officer
Period of report
Nov 15, 2017
Accepted (ET)
Nov 17, 2017 · 8:01 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1 | $5.90 | Nov 15, 2017 | A | 200,000 | A | — | Nov 14, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1One quarter of the options shall vest on November 14, 2018, subject to the completion of 12 months of continuous employment from the date of grant, and the balance shall vest in 36 monthly installments upon the completion of each month of continuous employment from the first anniversary of the date of grant.